Skip to main content

BioMarin Pharmaceutical (BMRN) Gets a Buy from Jefferies

Tipranks - Tipranks - Fri Feb 13, 9:06AM CST

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $113.00.

Valentine's Day Sale - 70% Off

Tewari covers the Healthcare sector, focusing on stocks such as Neurocrine, Argenx Se, and Alkermes. According to TipRanks, Tewari has an average return of 13.4% and a 56.55% success rate on recommended stocks.

In a report released on February 6, Piper Sandler also maintained a Buy rating on the stock with a $84.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on BioMarin Pharmaceutical’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $776.13 million and a GAAP net loss of $30.74 million. In comparison, last year the company earned a revenue of $745.74 million and had a net profit of $106.08 million

Read More on BMRN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).